Search

Your search keyword '"Motohashi, Nobutaka"' showing total 172 results
Start Over Author "Motohashi, Nobutaka"
172 results on '"Motohashi, Nobutaka"'

16. Chronic repetitive transcranial magnetic stimulation failed to change dopamine synthesis rate: Preliminary L-[beta-11C]DOPA positron emission tomography study in patients with depression

Author

Kuroda, Yuko, Motohashi, Nobutaka, Ito, Hiroshi, Ito, Shigeo, Takano, Akihiro, Takahashi, Hidehiko, Nishikawa, Touru, and Suhara, Tetsuya

Subjects
nervous system, musculoskeletal, neural, and ocular physiology, mental disorders, behavioral disciplines and activities, psychological phenomena and processes
Abstract

We have examined the effects of repetitive transcranial magnetic stimulation (rTMS) on central dopaminergic function in patients with depression using positron emission tomography with L-[beta-11C]DOPA, a ligand to assess the rate of endogenous dopamine synthesis. Eight patients were treated with 10-daily sessions of rTMS over the left dorsolateral prefrontal cortex. Positron emission tomography scanning was performed in each patient twice, before the first session and 1 day after the last session. Although four out of eight patients responded to rTMS, there were no changes in the striatal dopamine synthesis rate (k) following rTMS. These results suggest that chronic rTMS had a limited effect on the dopaminergic system.

Published
2010

20. GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate

Author

Motohashi Nobutaka

Subjects
Male, Baclofen, Lithium (medication), medicine.medical_treatment, In Vitro Techniques, Lithium, Pharmacology, GABAB receptor, Rats, Inbred WKY, chemistry.chemical_compound, GABA receptor, medicine, Animals, Biological Psychiatry, Muscimol, GABAA receptor, Valproic Acid, Brain, Carbamazepine, Receptors, GABA-A, Rats, Anticonvulsant, nervous system, chemistry, medicine.drug
Abstract

1. Effects of lithium, carbamazepine, sodium valproate and baclofen on GABA receptors were examined in several regions of the rat brain. 2. [3H]Muscimol (MUS) and [3H] (-)baclofen (BAC) were used to label GABAA and GABAB receptors, respectively, in synaptic membranes from rat brain. 3. Single treatment with lithium chloride, carbamazepine or sodium valproate did not change [3H]MUS or [3H]BAC binding in the frontal cortex, hippocampus and thalamus. 4. Following chronic treatment with lithium, carbamazepine or sodium valproate, [3H]BAC binding was significantly increased in the hippocampus but not in the frontal cortex, thalamus or striatum. 5. [3H]Muscimol binding did not change in any region examined after chronic treatment with lithium, carbamazepine or sodium valproate. 6. Single and chronic administration of baclofen did not change [3H]MUS or [3H]BAC binding. 7. One common mechanism of action of mood stabilizers may be mediated by GABAB receptors in the hippocampus.

Published
1992
Full Text
View/download PDF

22. Plasma Amyloid-β and Alzheimer's Disease-Related Changes in Late-Life Depression.

Author

Chiemi Yamazaki, Toshio Tamaoki, Akihiko Nunomura, Kenichi Tamai, Kazuyuki Yasuda, Nobutaka Motohashi, Yamazaki, Chiemi, Tamaoki, Toshio, Nunomura, Akihiko, Tamai, Kenichi, Yasuda, Kazuyuki, and Motohashi, Nobutaka

Subjects
AMYLOID beta-protein, ALZHEIMER'S patients, DEPRESSION in old age, PATHOLOGICAL physiology, BRAIN imaging, PSYCHOLOGY, ANTIDEPRESSANTS, MENTAL depression, ELECTROCONVULSIVE therapy, MAGNETIC resonance imaging, NEUROPSYCHOLOGICAL tests, PEPTIDES, PSYCHOLOGICAL tests
Abstract

To elucidate an involvement of amyloid dysmetabolism in the pathophysiology of depression, we investigated associations of plasma amyloid-β (Aβ) levels with Alzheimer's disease-related changes in neuroimaging and cognitive dysfunction in patients with late-life depression. Higher plasma Aβ40, but not Aβ42 nor Aβ40/Aβ42 ratio, was associated with higher degree of parahippocampal atrophy and lower verbal fluency performance. Indeed, high plasma Aβ40 predicted poor cognitive prognosis of depressed patients with mild cognitive impairment. As an anti-depressive treatment, electroconvulsive therapy (ECT) resulted in a marginally significant reduction of plasma Aβ40 compared to pharmacotherapy alone, suggesting protective effects of ECT against amyloid dysmetabolism. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

23. rTMS failed to change [11C]raclopride binding in depressed patinets

Author

Kuroda, Yuko, Motohashi, Nobutaka, Ito, Shigeo, Takano, Akihiro, Atsuta, Hidenori, Terada, Tomo, Suhara, Tetsuya, and Nishikawa, Touru

Subjects
education, social sciences, humanities, geographic locations, health care economics and organizations
Abstract

8ｔｈ world congress of biological psychiatry

Published
2005

24. Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder

Author

Ogawa, Shintaro, primary, Hattori, Kotaro, additional, Sasayama, Daimei, additional, Yokota, Yuki, additional, Matsumura, Ryo, additional, Matsuo, Junko, additional, Ota, Miho, additional, Hori, Hiroaki, additional, Teraishi, Toshiya, additional, Yoshida, Sumiko, additional, Noda, Takamasa, additional, Ohashi, Yoshiaki, additional, Sato, Hajime, additional, Higuchi, Teruhiko, additional, Motohashi, Nobutaka, additional, and Kunugi, Hiroshi, additional

Published
2015
Full Text
View/download PDF

25. PlasmaL-Tryptophan Concentration in Major Depressive Disorder

Author

Ogawa, Shintaro, primary, Fujii, Takashi, additional, Koga, Norie, additional, Hori, Hiroaki, additional, Teraishi, Toshiya, additional, Hattori, Kotaro, additional, Noda, Takamasa, additional, Higuchi, Teruhiko, additional, Motohashi, Nobutaka, additional, and Kunugi, Hiroshi, additional

Published
2014
Full Text
View/download PDF

27. An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia

Author

Hirano,Jinichi, Watanabe,Koichiro, Suzuki,Takefumi, Uchida,Hiroyuki, Den,Ryosuke, Kishimoto,Taishiro, Nagasawa,Takashi, Tomita,Yusuke, Hara,Koichiro, Ochi,Hiromi, Kobayashi,Yoshimi, Ishii,Mutsuko, Fujita,Akane, Kanai,Yoshihiko, Goto,Megumi, Hayashi,Hiromi, Inamura,Kanako, Ooshima,Fumiko, Sumida,Mariko, Ozawa,Tomoko, Sekigawa,Kayoko, Nagaoka,Maki, Yoshimura,Kae, Konishi,Mika, Inagaki,Ataru, Saito,Takuya, Motohashi,Nobutaka, Mimura,Masaru, Okubo,Yoshiro, Kato,Motoichiro, Hirano,Jinichi, Watanabe,Koichiro, Suzuki,Takefumi, Uchida,Hiroyuki, Den,Ryosuke, Kishimoto,Taishiro, Nagasawa,Takashi, Tomita,Yusuke, Hara,Koichiro, Ochi,Hiromi, Kobayashi,Yoshimi, Ishii,Mutsuko, Fujita,Akane, Kanai,Yoshihiko, Goto,Megumi, Hayashi,Hiromi, Inamura,Kanako, Ooshima,Fumiko, Sumida,Mariko, Ozawa,Tomoko, Sekigawa,Kayoko, Nagaoka,Maki, Yoshimura,Kae, Konishi,Mika, Inagaki,Ataru, Saito,Takuya, Motohashi,Nobutaka, Mimura,Masaru, Okubo,Yoshiro, and Kato,Motoichiro

Abstract

Jinichi Hirano,1,2 Koichiro Watanabe,3 Takefumi Suzuki,1,4 Hiroyuki Uchida,1 Ryosuke Den,5 Taishiro Kishimoto,1 Takashi Nagasawa,5 Yusuke Tomita,4 Koichiro Hara,6 Hiromi Ochi,7 Yoshimi Kobayashi,1 Mutsuko Ishii,1 Akane Fujita,1 Yoshihiko Kanai,1 Megumi Goto,1 Hiromi Hayashi,1 Kanako Inamura,1 Fumiko Ooshima,1 Mariko Sumida,1 Tomoko Ozawa,1 Kayoko Sekigawa,1 Maki Nagaoka,1 Kae Yoshimura,1 Mika Konishi,1 Ataru Inagaki,1 Takuya Saito,8 Nobutaka Motohashi,9 Masaru Mimura,1 Yoshiro Okubo,8 Motoichiro Kato,11Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan; 2Ohizumi Hospital, Tokyo, Japan; 3Department of Psychiatry School of Medicine, Kyorin University, Tokyo, Japan; 4Inokashira Hospital, Tokyo, Japan; 5Komagino Hospital, Tokyo, Japan; 6Asai Hospital, Chiba, Japan; 7Kurumegaoka Hospital, Tokyo, Japan; 8Department of Psychiatry School of Medicine, Nippon Medical School, Tokyo, Japan; 9Department of Psychiatry, School of Medicine, University of Yamanashi, Yamanashi, JapanObjective: The use of an algorithm may facilitate measurement-based treatment and result in more rational therapy. We conducted a 1-year, open-label study to compare various outcomes of algorithm-based treatment (ALGO) for schizophrenia versus treatment-as-usual (TAU), for which evidence has been very scarce.Methods: In ALGO, patients with schizophrenia (Diagnostic and Statistical Manual of Mental Disorders, fourth edition) were treated with an algorithm consisting of a series of antipsychotic monotherapies that was guided by the total scores in the positive and negative syndrome scale (PANSS). When posttreatment PANSS total scores were above 70% of those at baseline in the first and second stages, or above 80% in the 3rd stage, patients proceeded to the next treatment stage with different antipsychotics. In contrast, TAU represented the best clinical judgment by treating psychiatrists.Results: Forty-two patients (21 females, 39.0 ± 10.9 years-old) participated in t

Published
2013

29. TJS-010, a New Prescription of Kampa Medicine with Putative Antidepressive and Anxiolytic Properties. : A behavioral study using experimental models for depression and anxiety

Author

Tanra, Andi J., Kagaya, Ariyuki, Motohashi, Nobutaka, Uchitomi, Yosuke, and Yamawaki, Shigeto

Subjects
Kampa, Depression, Anxiety
Abstract

We investigated the effect of TJS-010, a new prescription of Kampo or oriental medicine, on the locomotor activity and body temperature in rats in order to determine its antidepressive and anxiolytic effects. Tetrabenazine(TBZ), which sometimes induces depression in humans, decreased the spontaneous locomotion in rats, and attenuated the content of amines in several regions in the rat brain when intraperitoneally injected. TJS-010 was orally administered at a concentration of 750 mg/kg, and inhibited the locomotor suppression. The content of amines was not, however, altered. These results indicate that TJS-010 postsynaptically modulates the transmission or transduction. Imipramine, 5mg/kg, also enhanced locomotion in TBZ-treated rats, which was similar to the effect of TJS-010. These results suggest that TJS-010 has an antidepressive effect. TJS-010 also facilitated the hypothermia induced by subcutaneous injection of 0.1 mg/kg ( ± )-8-hydroxy-2-(di-N-propylamino)tetralin (8-OH-DPAT), which is known to be mediated by serotonin-1A receptors. The hypothermia in the rats via an activation of serotonin-1A receptors is often observed with anxiolytic drugs. These results may raise the possibility that TJS-010 has an anxiolytic property. TJS-010 may serve as a useful drug for the treatment of those who suffer from depressive and anxiety disorders.

Published
1994

32. Clinical impact of 11 C-Pittsburgh compound- B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment

Author

Omachi, Yoshie, Ito, Kimiteru, Arima, Kunimasa, Matsuda, Hiroshi, Nakata, Yasuhiro, Sakata, Masuhiro, Sato, Noriko, Nakagome, Kazuyuki, and Motohashi, Nobutaka

Subjects
POSITRON emission tomography, MAGNETIC resonance imaging, SINGLE-photon emission computed tomography, ALZHEIMER'S disease diagnosis, DEMENTIA patients, MILD cognitive impairment, PATIENTS
Abstract

Aims The purpose of this study was to evaluate the clinical impact of addition of [11C]Pittsburgh compound-B positron emission tomography (11 C- PiB PET) on routine clinical diagnosis of Alzheimer's disease ( AD) dementia and mild cognitive impairment ( MCI), and to assess diagnostic agreement between clinical criteria and research criteria of the National Institute on Aging-Alzheimer's Association. Methods The diagnosis in 85 patients was made according to clinical criteria. Imaging examinations, including both magnetic resonance imaging and single-photon emission computed tomography/computed tomography to identify neuronal injury ( NI), and 11 C- PiB PET to identify amyloid were performed, and all subjects were re-categorized according to the research criteria. Results Among 40 patients with probable AD dementia ( ProAD), 37 were NI-positive, 29 were 11 C- PiB-positive, and 27 who were both NI- and 11 C- PiB-positive were categorized as having ' ProAD dementia with a high level of evidence of the AD pathophysiological process'. Among 20 patients with possible AD dementia ( PosAD), 17 were NI-positive, and six who were both NI- and 11 C- PiB-positive were categorized as having ' PosAD with evidence of the AD pathophysiological process'. Among 25 patients with MCI, 18 were NI-positive, 13 were 11 C- PiB-positive, and 10 who were both NI- and 11 C- PiB-positive were categorized as having ' MCI due to AD-high likelihood'. Conclusions Diagnostic concordance between clinical criteria and research criteria may not be high in this study. 11 C- PiB PET may be of value in making the diagnosis of dementia and MCI in cases with high diagnostic uncertainty. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

34. Neural Mechanism of Propofol Anesthesia in Severe Depression

Author

Ogawa, Kenichi, primary, Uema, Takeshi, additional, Motohashi, Nobutaka, additional, Nishikawa, Masami, additional, Takano, Harumasa, additional, Hiroki, Masahiko, additional, Imabayashi, Etsuko, additional, Ohnishi, Takashi, additional, Inoue, Tomio, additional, Takayama, Yutaka, additional, Takeda, Masatoshi, additional, Matsuda, Hiroshi, additional, Andoh, Tomio, additional, and Yamada, Yoshitsugu, additional

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results